Search Results

Ascentage Pharma, a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B, and age-related diseases, announced that the agreed equity investment by Takeda has been closed on June 20, 2024, with all proceeds already received.

Ascentage Pharma announced that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission relating to the proposed initial public offering of American depositary shares representing its ordinary shares.

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its annual results for the full year 2023.

Ascentage Pharma announced that its four abstracts selected for presentations at the 2024 American Society of Clinical Oncology Annual Meeting are now available on ASCO’s official website.

Ascentage Pharma announced that it has released updated results from a global, multicenter Phase Ib/II study of the Bcl-2 inhibitor lisaftoclax alone or in combinations for the treatment of patients with Waldenström macroglobulinemia, in a poster presentation at the 60th American Society of Clinical Oncology Annual Meeting taking place in Chicago, IL.

Ascentage Pharma (6855 HK) announced today the signing of an option agreement with Takeda to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers.

Ascentage Pharma announced that the latest results from five studies have been selected for Poster Presentations at the 2024 European Hematology Association Hybrid Congress.

Ascentage Pharma announced that it has released updated data of the Bcl-2 inhibitor lisaftoclax, one of the company’s key drug candidates, combined with novel therapeutic regimens in patients with relapsed/refractory multiple myeloma or immunoglobulin light-chain amyloidosis, in a poster presentation at the 2024 European Hematology Association Hybrid Congress, taking place in Madrid, Spain.

Ascentage Pharma announced that it has released updated data of its novel drug candidate AGP-2449, a FAK/ALK/ROS1 tyrosine kinase inhibitor, in patients with non-small-cell lung cancer in a poster presentation at the 60th American Society of Clinical Oncology Annual Meeting taking place in Chicago, IL.

Ascentage Pharma announced that results from four clinical studies of the company’s three key drug candidates have been selected for presentations, including an Oral Report, at the 2024 American Society of Clinical Oncology Annual Meeting.